Cardiogen

Cardiogen is a synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), developed as a cardiac muscle bioregulator by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. It is derived from bovine cardiac tissue and proposed to promote cardiomyocyte survival and proliferation through epigenetic mechanisms.

Cardiogen's research evidence consists of organotypic rat myocardial culture experiments demonstrating cardiomyocyte proliferation and anti-apoptotic effects at picomolar concentrations — results reported in review articles by the developing research group. No independent replication, Western peer-reviewed animal studies, or human clinical trials have been published.

Cardiogen is proposed to act through the Khavinson-class peptide-DNA interaction mechanism: the AEDR tetrapeptide enters cell nuclei and interacts with regulatory DNA sequences or chromatin proteins in cardiomyocytes to modulate gene expression programs governing cell cycle re-entry and survival.

In organotypic myocardial tissue cultures (rat), published results from Khavinson's group describe: - Stimulation of cardiomyocyte proliferation at 10⁻¹⁴ to 10⁻¹² mol/L — a concentration range suggesting high-affinity interaction with nuclear targets - Decreased p53 expression — consistent with reduced apoptotic signaling - Increased Ki-67 — proliferation marker indicating cell cycle activity in post-mitotic cardiomyocytes - Specificity to the tetrapeptide (no single amino acid substitution reproduces the full effect)

This cardiomyocyte proliferation claim is pharmacologically notable because mature cardiomyocytes are largely post-mitotic in adult mammals — the proposed induction of proliferative activity in aged cardiomyocytes would represent a significant biological effect. However, this claim has not been independently validated.